Patents Assigned to Munich GmbH
-
Patent number: 10683351Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising the polynucleotide and a host cell transformed or transfected with the polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of the antibody construct and a kit comprising the antibody construct.Type: GrantFiled: March 4, 2019Date of Patent: June 16, 2020Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Tobias Raum, Claudia Blümel, Christoph Dahlhoff, Patrick Hoffmann, Peter Kufer, Ralf Lutterbüse, Elisabeth Nahrwold, Jochen Pendzialek
-
Patent number: 10662243Abstract: The disclosure provides a method for assessing the risk of potential adverse effects for a human patient mediated by the administration of a CD19×CD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient. The disclosure also provides a method for administering a CD19×CD3 bispecific antibody to a human patient having a B:T cell ratio of about 1:5 or lower, comprising administering doses in a dosing regimen. This dosing regimen can be applied in methods for treating malignant CD19 positive lymphocytes or for ameliorating and/or preventing an adverse effect mediated by the administration of said bispecific antibody. The Also provided is a pharmaceutical package or kit comprising a first dose and a second dose and optionally a third dose of said antibody.Type: GrantFiled: September 19, 2014Date of Patent: May 26, 2020Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Dirk Nagorsen, Peter Kufer, Gerhard Zugmaier, Patrick Bauerle
-
Publication number: 20200061750Abstract: Methods and apparatuses are disclosed for laser processing. A method includes providing a laser beam transparent to a workpiece. A cover, having a surface quality better than the workpiece's surface, is provided and spaced apart from the workpiece's surface. A fluid is provided between and in contact with the cover and the workpiece's surface. A laser beam is directed through the cover and fluid to the workpiece. An apparatus includes a cover spaced apart from a workpiece's surface and including a surface quality better than the workpiece's surface, a fluid dispenser for introducing fluid between and in contact with the cover and the workpiece's surface, and a laser system that directs a laser beam through the cover and fluid to the workpiece.Type: ApplicationFiled: August 22, 2018Publication date: February 27, 2020Applicant: Coherent Munich GmbH & Co. KGInventors: Urs EPPELT, Ludger MÜLLERS, Anthony S. Lee
-
Publication number: 20200030917Abstract: A method for separating and releasing a closed-form piece from a workpiece made of a brittle material is disclosed. A first pulsed laser-beam creates defects along the outline of the closed-form piece. A second laser-beam selectively heats the closed-form piece for a first time that is sufficient to initiate cracking between the defects. The heating is stopped for a period sufficiently long for the cracks to propagate completely between the defects. The second laser-beam is applied for a second time that causes melting and deformation of the closed-form piece. The deformation opens a gap between the closed-form piece and the rest of the workpiece, thereby allowing release of the closed-form piece.Type: ApplicationFiled: July 11, 2019Publication date: January 30, 2020Applicant: Coherent Munich GmbH & Co. KGInventors: Stefan GRONINGER, Manfred SCHADI, Ludger MÜLLERS, Jürgen SERBIN
-
Patent number: 10519241Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human EGFRVIII on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: GrantFiled: August 1, 2016Date of Patent: December 31, 2019Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Tobias Raum, Ines Herrmann, Patrick Hoffmann, Peter Kufer, Markus Muenz, Doris Rau
-
Patent number: 10301391Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3? chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.Type: GrantFiled: February 2, 2017Date of Patent: May 28, 2019Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.Inventors: Tobias Raum, Markus Münz, Johannes Brozy, Peter Kufer, Patrick Hoffmann, Matthias Friedrich, Benno Rattel, Pamela Bogner, Andreas Wolf, Cornelius Pompe
-
Patent number: 10294300Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: GrantFiled: August 1, 2016Date of Patent: May 21, 2019Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Tobias Raum, Claudia Blümel, Christoph Dahlhoff, Patrick Hoffmann, Peter Kufer, Ralf Lutterbüse, Elisabeth Nahrwold, Jochen Pendzialek
-
Patent number: 10191034Abstract: A method for assessing the risk of potential adverse effects for a human patient receiving a CD19×CD3 bispecific antibody is provided. The method comprises determining the total B count in the patient, and identifying a B cell number indicative of a patient at risk of potential adverse effects from the antibody. The method further provides a dosing schedule for administering the antibody to the patient identified as at risk of potential adverse effects. Also provided is a pharmaceutical package or kit comprising a first dose and a second dose, and optionally a third dose, of the CD19×CD3 bispecific antibody as defined in the methods/dosage regimen of the disclosure.Type: GrantFiled: April 30, 2012Date of Patent: January 29, 2019Assignee: AMGEN RESEARCH (MUNICH) GMBHInventor: Dirk Nagorsen
-
Patent number: 10138297Abstract: The present invention relates to a human monoclonal antibody or fragment thereof which specifically binds to and neutralizes primate GM-CSF.Type: GrantFiled: May 21, 2015Date of Patent: November 27, 2018Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Tobias Raum, Julia Hepp (nee Henckel), Eva Vieser (nee Krinner), Silke Petsch (nee Mittelstrass), Steven Zeman, Andreas Wolf, Sandra Bruckmaier
-
Patent number: 10130638Abstract: The present invention relates to a glucocorticoid (GC) for use in the amelioration, treatment or prophylaxis of neurological/psychiatric adverse events caused by a CD3 binding domain. Kits comprising a GC, a CD3 binding domain and instructions for use which indicate that the GC is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed.Type: GrantFiled: October 27, 2011Date of Patent: November 20, 2018Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Gerhard Zugmaier, Dirk Nagorsen, Juergen Scheele
-
Patent number: 10059766Abstract: The invention provides a bispecific antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention provides a nucleic acid encoding the antibody construct, a vector comprising the nucleic acid and a host cell transformed or transfected with the vector. Furthermore, the invention provides a process for the production of the bispecific antibody construct, a medical use of the antibody construct and a kit comprising the antibody construct. The bispecific antibody construct may be useful in the treatment of melanoma.Type: GrantFiled: January 27, 2014Date of Patent: August 28, 2018Assignees: AMGEN INC., AMGEN RESEARCH (MUNICH) GMBHInventors: Shouhua Xiao, Zheng Pan, Dineli Wickramasinghe, M. Shawn Jeffries, Chadwick Terence King, Brian Mingtung Chan, Peter Kufer, Ralf Lutterbüse, Tobias Raum, Patrick Hoffmann, Doris Rau, Roman Kischel, Bryan Lemon, Holger Wesche
-
Patent number: 10047159Abstract: The present invention provides a method for the selection of bispecific single chain antibodies comprising a first binding domain capable of binding to an epitope of CD3 and a second binding domain capable of binding to the extracellular do main cell surface antigens with a high molecular weight extracellular domain. Moreover, the invention provides bispecific single chain antibodies produced by the use of the method of the invention, nucleic acid molecules encoding these antibodies, vectors comprising such nucleic acid molecules and methods for the production of the antibodies. Furthermore, the invention provides pharmaceutical compositions comprising bispecific single chain antibodies of the invention, medical uses of the same and methods for the treatment of diseases comprising the administration of bispecific single chain antibodies of the invention.Type: GrantFiled: January 8, 2016Date of Patent: August 14, 2018Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Peter Kufer, Claudia Blümel, Roman Kischel
-
Patent number: 10000574Abstract: The present invention relates to compositions comprising polypeptides, especially polypeptides capable of specifically binding predetermined antigens. The polypeptide in the composition comprises at least two antigen binding sites. These at least two antigen binding sites are located on a single polypeptide chain. One of the at least two antigen binding sites specifically binds the human CD3 antigen. The polypeptide may exist in both monomeric form and multimeric form. The multimeric form of the polypeptide constitutes no more than 5% of the total weight of the combined monomeric and multimeric forms of said polypeptide.Type: GrantFiled: November 26, 2004Date of Patent: June 19, 2018Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Robert Hofmeister, Nadja Prang, Andreas Wolf, Frank Hanakam, Thomas Urbig, Christian Itin, Patrick Baeuerle
-
Patent number: 9982063Abstract: The present disclosure relates to a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, where the second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7, a pharmaceutical composition comprising the bispecific single chain antibody, and methods for the treatment of an epithelial tumor in a human with the pharmaceutical compositions containing the bispecific single chain antibody. Furthermore, processes for the production of the pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed.Type: GrantFiled: September 19, 2016Date of Patent: May 29, 2018Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Ralf Lutterbüse, Petra Fluhr, Evelyne Schaller, Doris Rau, Susanne Mangold, Peter Kufer, Alexander Murr, Tobias Raum, Monika Wissinger
-
Patent number: 9919051Abstract: The present invention relates to aqueous formulations comprising a compound neutralizing GM-CSF in concentrations of at least about 20 mg/ml, a tonicity modifier and a buffer, wherein the composition is stable. The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of long-term storage. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders. Furthermore, a kit comprising the formulation of the invention is provided.Type: GrantFiled: October 31, 2013Date of Patent: March 20, 2018Assignees: Amgen Research (Munich) GmbH, Takeda GmbHInventors: Thomas Urbig, Thomas Boehm, Wolfram Steinhilber, Michael Molhoj
-
Patent number: 9833410Abstract: The present invention relates to aqueous formulations comprising at least 20 mg/ml of a compound neutralizing GM-CSF, a lyoprotectant and an amino acid and/or a buffer. The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of lyophilization, storage and reconstruction. In a preferred aspect, the formulation, e.g. after reconstruction, is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders. Furthermore, a kit comprising the formulation of the invention is provided.Type: GrantFiled: October 31, 2013Date of Patent: December 5, 2017Assignees: Takeda GmbH, Amgen Research (Munich) GmbHInventors: Markus Rast, Wolfram Steinhilber, Christian de Muynck, Gerhard Becker, Pernille Dybendal Pedersen, Thomas Urbig, Thomas Boehm
-
Patent number: 9765157Abstract: The present invention provides a bispecific antibody construct comprising a first human binding domain which binds to human CDH19 on the surface of a target cell and a second binding domain which binds a human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising the polynucleotide and a host cell transformed or transfected with the polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of the antibody construct in the treatment of melanoma, and a kit comprising the antibody construct.Type: GrantFiled: July 31, 2015Date of Patent: September 19, 2017Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Shouhua Xiao, Zheng Pan, Dineli Wickramasinghe, Peter Kufer, Patrick Hoffmann, Tobias Raum, Ralf Lutterbüse, Elisabeth Nahrwold, Claudia Blumel
-
Patent number: 9695250Abstract: The present disclosure relates to a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, where the second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7, a pharmaceutical composition comprising the bispecific single chain antibody, and methods for the treatment of an epithelial tumor in a human with the pharmaceutical compositions containing the bispecific single chain antibody. Furthermore, processes for the production of the pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed.Type: GrantFiled: January 14, 2013Date of Patent: July 4, 2017Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Ralf Lutterbüse, Petra Fluhr, Evelyne Schaller, Doris Rau, Susanne Mangold, Peter Kufer, Alexander Murr, Tobias Raum, Monika Wissinger
-
Patent number: 9688760Abstract: The present invention relates in essence to use of a compound, which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by a therapy which comprises re-directing of T-cells against target cells in a patient. Such a therapy includes, but is not limited to, treatment with an antibody comprising a CD3 binding domain, such as a CD20×CD3 or a CD19×CD3 bispecific single chain antibody, e.g., blinatumomab (MT-103). Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated, as are methods of identifying a compound for administration in the methods of prophylaxis, amelioration and/or treatment.Type: GrantFiled: February 8, 2014Date of Patent: June 27, 2017Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Peter Kufer, Dirk Nagorsen, Juergen Scheele, Gerhard Zugmaier, Matthias Klinger, Patrick Hoffmann, Virginie Naegele, Elaine-Pashupati Dopfer
-
Patent number: 9598500Abstract: The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.Type: GrantFiled: November 15, 2012Date of Patent: March 21, 2017Assignees: Amgen Inc., Amgen Research (Munich) GMBHInventors: Peter Kufer, Tobias Raum, Patrick Hoffmann, Roman Kischel, Ralf Lutterbuese, Doris Rau, Paul Adam, Eric Borges, Barbara Hebeis, Susanne Hipp